+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sunitinib"

From
From
Sunitinib Malate - Global Strategic Business Report - Product Thumbnail Image

Sunitinib Malate - Global Strategic Business Report

  • Report
  • March 2025
  • 193 Pages
  • Global
From
Kidney Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Kidney Cancer Drugs - Global Strategic Business Report

  • Report
  • February 2025
  • 148 Pages
  • Global
From
From
Gastric Cancer Drugs Market Report 2025 - Product Thumbnail Image

Gastric Cancer Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Kidney Cancer Drugs Market Report 2025 - Product Thumbnail Image

Kidney Cancer Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
From
From
Neuroendocrine Tumors - Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Neuroendocrine Tumors - Market Insight, Epidemiology and Market Forecast - 2034

  • Drug Pipelines
  • September 2024
  • 247 Pages
  • Global
From
Renal Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Renal Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
Esophageal Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Esophageal Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 250 Pages
  • Global
From
Soft Tissue Sarcoma - Pipeline Insight, 2024 - Product Thumbnail Image

Soft Tissue Sarcoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 250 Pages
  • Global
From
Pancreatic Cancer Pipeline Analysis Report - Product Thumbnail Image

Pancreatic Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Precision Cancer Therapeutics, 2022 - Product Thumbnail Image

Precision Cancer Therapeutics, 2022

  • Report
  • November 2022
  • 154 Pages
  • Global
From
Loading Indicator

Sunitinib is an oncology drug used to treat a variety of cancers, including gastrointestinal stromal tumors, renal cell carcinoma, and pancreatic neuroendocrine tumors. It is a tyrosine kinase inhibitor, meaning it works by blocking the action of certain proteins that can cause cancer cells to grow and divide. Sunitinib is typically administered orally, and is available in both capsule and tablet form. Sunitinib is a relatively new drug, having been approved by the US Food and Drug Administration in 2006. It has since become a popular treatment option for many types of cancer, due to its effectiveness and relatively low side effects. Sunitinib is also used in combination with other drugs to treat certain types of cancer, such as advanced renal cell carcinoma. Some of the companies in the Sunitinib market include Pfizer, Novartis, and AstraZeneca. These companies manufacture and distribute the drug, as well as provide support and resources for patients and healthcare professionals. Show Less Read more